person · Reporting owner

Stephenson Pamela

Disclosed activity across 3 companies

Tapewire entity: 66220
SEC CIK: 0001767650

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Disc Medicine, Inc.IRON · Entity 2273	Chief Commercial Officer	February 17, 2026	February 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Disc Medicine, Inc.

Report date February 17, 2026 · Filed February 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	80,998	Reported balance After 2026-02-17 transaction · row 1 1 source row Row 1 · 2026-02-17 · Sale · Disposed 5,531 · Balance 80,998 F1: This transaction represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I. This sale is a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I. This sale is a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ALBIREO PHARMA, INC.

Report date March 02, 2023 · Filed March 02, 2023

Section 16 reporting ended · disclosed 2023-03-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-03-02 transaction · row 1 1 source row Row 1 · 2023-03-02 · Other · Disposed 22,242 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the "Merger Agreement"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee ("Guarantor"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of March 2, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was canceled and converted into the right to receive $42.00 in cash, without interest (the "Closing Amount") F2: (Continued from Footnote 1) plus one non-tradeable contractual contingent value right ("CVR" and each CVR together with the Closing Amount, the "Offer Price"), which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement (the "CVR Agreement") on or prior to December 31, 2027 (the "Milestone").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.88 · Expires 2031-01-20	Direct	Reported balance After 2023-03-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-03-02 · Disposition to issuer · Disposed 23,700 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") F4: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.67 · Expires 2030-01-20	Direct	Reported balance After 2023-03-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-03-02 · Disposition to issuer · Disposed 31,500 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") F4: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.76 · Expires 2029-03-24	Direct	Reported balance After 2023-03-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-03-02 · Disposition to issuer · Disposed 37,500 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") F4: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-03-02 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-03-02 · Disposition to issuer · Disposed 75,513 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one Share. F6: Pursuant to the terms of the Merger Agreement, (a) each outstanding restricted stock unit (each, a "Company RSU") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an "Accelerated 2023 RSU," was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one CVR for each Share subject to such Company RSU immediately prior to the Effective Time; and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a "Cancelled 2023 RSU" was canceled and had no further force or effect. F7: Not applicable.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the "Merger Agreement"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee ("Guarantor"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of March 2, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was canceled and converted into the right to receive $42.00 in cash, without interest (the "Closing Amount")

F2: (Continued from Footnote 1) plus one non-tradeable contractual contingent value right ("CVR" and each CVR together with the Closing Amount, the "Offer Price"), which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement (the "CVR Agreement") on or prior to December 31, 2027 (the "Milestone").

F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option")

F4: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect.

F5: Each restricted stock unit represents a contingent right to receive one Share.

F6: Pursuant to the terms of the Merger Agreement, (a) each outstanding restricted stock unit (each, a "Company RSU") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an "Accelerated 2023 RSU," was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one CVR for each Share subject to such Company RSU immediately prior to the Effective Time; and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a "Cancelled 2023 RSU" was canceled and had no further force or effect.

F7: Not applicable.

Zynerba Pharmaceuticals, Inc.

Report date October 10, 2023 · Filed October 11, 2023

Section 16 reporting ended · disclosed 2023-10-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2023-10-10 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2023-10-10 · Other · Disposed 27,954 · Balance 47,824 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 14, 2023, by and among the Issuer, Harmony Biosciences Holdings, Inc., a Delaware corporation ("Parent") and Xylophone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer (the "Offer") for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of October 10, 2023 (the "Effective Time" with the Issuer surviving the merger). (continued in footnote 2) F2: (Continued from footnote 1) At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $1.1059 per Share (the "Cash Amount") in cash, subject to any applicable withholding taxes and without interest, plus (b) one contingent value right (each, a "CVR") per Share (the "CVR Amount" and together with the Cash Amount, the "Merger Consideration"), which represents the right to receive up to approximately $2.5444 per Share in the form of one or more potential contingent payments, in cash, subject to any applicable withholding taxes and without interest, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment"). Row 2 · 2023-10-10 · Other · Disposed 47,824 · Balance 0 F3: This line item represents unvested restricted stock awards ("RSAs") held by the Reporting Person that were tendered pursuant to the Offer. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time and not validly tendered in the Offer was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.01 · Expires 2032-06-14	Direct	Reported balance After 2023-10-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-10-10 · Disposition to issuer · Disposed 34,663 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 5) F5: (Continued from footnote 4) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.35 · Expires 2033-06-13	Direct	Reported balance After 2023-10-10 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-10-10 · Disposition to issuer · Disposed 71,736 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 5) F5: (Continued from footnote 4) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 14, 2023, by and among the Issuer, Harmony Biosciences Holdings, Inc., a Delaware corporation ("Parent") and Xylophone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer (the "Offer") for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of October 10, 2023 (the "Effective Time" with the Issuer surviving the merger). (continued in footnote 2)

F2: (Continued from footnote 1) At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $1.1059 per Share (the "Cash Amount") in cash, subject to any applicable withholding taxes and without interest, plus (b) one contingent value right (each, a "CVR") per Share (the "CVR Amount" and together with the Cash Amount, the "Merger Consideration"), which represents the right to receive up to approximately $2.5444 per Share in the form of one or more potential contingent payments, in cash, subject to any applicable withholding taxes and without interest, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment").

F3: This line item represents unvested restricted stock awards ("RSAs") held by the Reporting Person that were tendered pursuant to the Offer. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time and not validly tendered in the Offer was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 5)

F5: (Continued from footnote 4) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 17, 2026 Filed Feb 18, 2026 02:15 UTC	Disc Medicine, Inc. IRON · Entity 2273	SaleCommon Stock	5,531	$62.86	$347,678.66	Disclosure SEC source: 0001193125-26-055646 · ownership.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,998 F1 · kind: This transaction represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I. This sale is a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document
February 10, 2026 Filed Feb 12, 2026 00:46 UTC	Disc Medicine, Inc. IRON · Entity 2273	GrantStock Option (Right to Buy) · Derivative	25,500	$0.00 Strike: $74.75	$0.00	Disclosure SEC source: 0001193125-26-047198 · ownership.xml · derivative · entry 2 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,500 Underlying: Common Stock · 25,500 shares Expires 2036-02-09 F2 · derivative.exercise_date: The shares underlying this option vest in 48 equal monthly installments commencing on March 10, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document
February 10, 2026 Filed Feb 12, 2026 00:46 UTC	Disc Medicine, Inc. IRON · Entity 2273	GrantCommon Stock	17,000	$0.00	$0.00	Disclosure SEC source: 0001193125-26-047198 · ownership.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,529 F1 · shares: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest annually in four 25% installments commencing on February 15, 2027, subject to the Reporting Person's continued service on each such vesting date. Read SEC document
February 18, 2025 Filed Feb 21, 2025 00:38 UTC	Disc Medicine, Inc. IRON · Entity 2273	SaleCommon Stock	3,137	$54.58	$171,217.46	Disclosure SEC source: 0000950170-25-024477 · ownership.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,529 F1 · kind: This transaction represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain restricted stock units granted on February 26, 2024 and previously reported in Table I. This sale is a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document
February 10, 2025 Filed Feb 12, 2025 23:48 UTC	Disc Medicine, Inc. IRON · Entity 2273	GrantStock Option (Right to Buy) · Derivative	36,000	$0.00 Strike: $54.71	$0.00	Disclosure SEC source: 0000950170-25-019106 · ownership.xml · derivative · entry 2 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2035-02-09 F2 · derivative.exercise_date: The shares underlying this option vest in 48 equal monthly installments commencing on March 10, 2025, subject to the Reporting Person's continuted service on each such vesting date. Read SEC document
February 10, 2025 Filed Feb 12, 2025 23:48 UTC	Disc Medicine, Inc. IRON · Entity 2273	GrantCommon Stock	36,000	$0.00	$0.00	Disclosure SEC source: 0000950170-25-019106 · ownership.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,666 F1 · shares: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest annually in four 25% installments commencing on February 15, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document
February 26, 2024 Filed Feb 27, 2024 22:38 UTC	Disc Medicine, Inc. IRON · Entity 2273	GrantStock Option (Right to Buy) · Derivative	55,000	$0.00 Strike: $64.66	$0.00	Disclosure SEC source: 0000950170-24-021448 · ownership.xml · derivative · entry 2 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2034-02-25 F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on February 26, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document
February 26, 2024 Filed Feb 27, 2024 22:38 UTC	Disc Medicine, Inc. IRON · Entity 2273	GrantCommon Stock	36,666	$0.00	$0.00	Disclosure SEC source: 0000950170-24-021448 · ownership.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,666 Read SEC document
October 10, 2023 Filed Oct 11, 2023 10:12 UTC	Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058	Disposition to issuerStock Option (Right to Buy) · Derivative	71,736	Not disclosed Strike: $0.35	Not disclosed	Disclosure SEC source: 0001140361-23-047743 · form4.xml · derivative · entry 4 Stephenson Pamela · CIK 0001767650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 71,736 shares Expires 2033-06-13 F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 5) F5 · price: (Continued from footnote 4) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 5) F5 · derivative.exercise_date: (Continued from footnote 4) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. Read SEC document
October 10, 2023 Filed Oct 11, 2023 10:12 UTC	Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058	Disposition to issuerStock Option (Right to Buy) · Derivative	34,663	Not disclosed Strike: $1.01	Not disclosed	Disclosure SEC source: 0001140361-23-047743 · form4.xml · derivative · entry 3 Stephenson Pamela · CIK 0001767650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,663 shares Expires 2032-06-14 F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 5) F5 · price: (Continued from footnote 4) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 5) F5 · derivative.exercise_date: (Continued from footnote 4) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. Read SEC document
October 10, 2023 Filed Oct 11, 2023 10:12 UTC	Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058	OtherCommon Stock	47,824	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-23-047743 · form4.xml · nonDerivative · entry 2 Stephenson Pamela · CIK 0001767650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · shares: This line item represents unvested restricted stock awards ("RSAs") held by the Reporting Person that were tendered pursuant to the Offer. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time and not validly tendered in the Offer was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest. F3 · price: This line item represents unvested restricted stock awards ("RSAs") held by the Reporting Person that were tendered pursuant to the Offer. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time and not validly tendered in the Offer was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest. Read SEC document
October 10, 2023 Filed Oct 11, 2023 10:12 UTC	Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058	OtherCommon Stock	27,954	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-23-047743 · form4.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,824 F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 14, 2023, by and among the Issuer, Harmony Biosciences Holdings, Inc., a Delaware corporation ("Parent") and Xylophone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer (the "Offer") for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of October 10, 2023 (the "Effective Time" with the Issuer surviving the merger). (continued in footnote 2) F2 · price: (Continued from footnote 1) At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $1.1059 per Share (the "Cash Amount") in cash, subject to any applicable withholding taxes and without interest, plus (b) one contingent value right (each, a "CVR") per Share (the "CVR Amount" and together with the Cash Amount, the "Merger Consideration"), which represents the right to receive up to approximately $2.5444 per Share in the form of one or more potential contingent payments, in cash, subject to any applicable withholding taxes and without interest, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment"). Read SEC document
June 14, 2023 Filed Jun 15, 2023 16:30 UTC	Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058	SaleCommon Stock	115	$0.35	$40.03	Disclosure SEC source: 0001062993-23-013668 · form4.xml · nonDerivative · entry 2 Stephenson Pamela · CIK 0001767650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,778 F2 · shares: This transaction represents shares required to be sold by the Reporting Person to satisfy certain equity plan administrator fees and taxes in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person. Read SEC document
June 13, 2023 Filed Jun 15, 2023 16:30 UTC	Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058	GrantStock Option (right to buy) · Derivative	71,736	$0.00 Strike: $0.35	$0.00	Disclosure SEC source: 0001062993-23-013668 · form4.xml · derivative · entry 3 Stephenson Pamela · CIK 0001767650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,736 Underlying: Common Stock · 71,736 shares Expires 2033-06-13 F3 · derivative.exercise_date: The option vests in full upon the earlier of (i) June 13, 2024 or (ii) the day before the Company's 2024 annual meeting of stockholders. Read SEC document
June 13, 2023 Filed Jun 15, 2023 16:30 UTC	Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058	GrantCommon Stock	47,824	$0.00	$0.00	Disclosure SEC source: 0001062993-23-013668 · form4.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,893 F1 · shares: The restricted stock award vests in full upon the earlier of (i) June 13, 2024 or (ii) the day before the Company's 2024 annual meeting of stockholders. Read SEC document
March 02, 2023 Filed Mar 2, 2023 16:54 UTC	ALBIREO PHARMA, INC. ALBO · Entity 116015	Disposition to issuerRestricted Stock Units · Derivative	75,513	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-014769 · doc4.xml · derivative · entry 5 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,513 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one Share. F6 · price: Pursuant to the terms of the Merger Agreement, (a) each outstanding restricted stock unit (each, a "Company RSU") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an "Accelerated 2023 RSU," was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one CVR for each Share subject to such Company RSU immediately prior to the Effective Time; and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a "Cancelled 2023 RSU" was canceled and had no further force or effect. F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, (a) each outstanding restricted stock unit (each, a "Company RSU") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an "Accelerated 2023 RSU," was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one CVR for each Share subject to such Company RSU immediately prior to the Effective Time; and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a "Cancelled 2023 RSU" was canceled and had no further force or effect. F7 · derivative.expiration_date: Not applicable. Read SEC document
March 02, 2023 Filed Mar 2, 2023 16:54 UTC	ALBIREO PHARMA, INC. ALBO · Entity 116015	Disposition to issuerStock Option (right to buy) · Derivative	37,500	Not disclosed Strike: $28.76	Not disclosed	Disclosure SEC source: 0001209191-23-014769 · doc4.xml · derivative · entry 4 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2029-03-24 F3 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") F4 · price: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect. F3 · derivative.exercise_date: Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") F4 · derivative.exercise_date: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect. Read SEC document
March 02, 2023 Filed Mar 2, 2023 16:54 UTC	ALBIREO PHARMA, INC. ALBO · Entity 116015	Disposition to issuerStock Option (right to buy) · Derivative	31,500	Not disclosed Strike: $24.67	Not disclosed	Disclosure SEC source: 0001209191-23-014769 · doc4.xml · derivative · entry 3 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,500 shares Expires 2030-01-20 F3 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") F4 · price: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect. F3 · derivative.exercise_date: Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") F4 · derivative.exercise_date: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect. Read SEC document
March 02, 2023 Filed Mar 2, 2023 16:54 UTC	ALBIREO PHARMA, INC. ALBO · Entity 116015	Disposition to issuerStock Option (right to buy) · Derivative	23,700	Not disclosed Strike: $34.88	Not disclosed	Disclosure SEC source: 0001209191-23-014769 · doc4.xml · derivative · entry 2 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,700 shares Expires 2031-01-20 F3 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") F4 · price: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect. F3 · derivative.exercise_date: Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") F4 · derivative.exercise_date: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect. Read SEC document
March 02, 2023 Filed Mar 2, 2023 16:54 UTC	ALBIREO PHARMA, INC. ALBO · Entity 116015	OtherCommon Stock	22,242	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-014769 · doc4.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the "Merger Agreement"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee ("Guarantor"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of March 2, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was canceled and converted into the right to receive $42.00 in cash, without interest (the "Closing Amount") F2 · kind: (Continued from Footnote 1) plus one non-tradeable contractual contingent value right ("CVR" and each CVR together with the Closing Amount, the "Offer Price"), which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement (the "CVR Agreement") on or prior to December 31, 2027 (the "Milestone"). F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the "Merger Agreement"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee ("Guarantor"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of March 2, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was canceled and converted into the right to receive $42.00 in cash, without interest (the "Closing Amount") F2 · price: (Continued from Footnote 1) plus one non-tradeable contractual contingent value right ("CVR" and each CVR together with the Closing Amount, the "Offer Price"), which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement (the "CVR Agreement") on or prior to December 31, 2027 (the "Milestone"). Read SEC document
January 23, 2023 Filed Jan 23, 2023 17:12 UTC	ALBIREO PHARMA, INC. ALBO · Entity 116015	SaleCommon Stock	102	$43.80	$4,467.60	Disclosure SEC source: 0001209191-23-004459 · doc4.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,755 F1 · shares: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Represents 22,242 shares of common stock and 20,513 restricted stock units. Read SEC document
January 19, 2023 Filed Jan 20, 2023 16:05 UTC	ALBIREO PHARMA, INC. ALBO · Entity 116015	SaleCommon Stock	1,774	$43.90	$77,886.41	Disclosure SEC source: 0001209191-23-004225 · doc4.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,857 F1 · shares: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.90 to $43.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: Represents 22,000 shares of common stock and 20,857 restricted stock units. Read SEC document
January 19, 2023 Filed Jan 25, 2023 20:07 UTC	ALBIREO PHARMA, INC. ALBO · Entity 116015	GrantCommon Stock	55,000	$0.00	$0.00	Disclosure SEC source: 0001209191-23-004947 · doc4.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,755 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 19, 2024, with the remainder vesting in equal installments every three months thereafter beginning on April 19, 2024 and ending on January 19, 2027. F2 · balance_after: Represents 22,242 shares of common stock and 75,513 restricted stock units. Read SEC document
January 19, 2023 Filed Jan 27, 2023 17:23 UTC Amendment	ALBIREO PHARMA, INC. ALBO · Entity 116015	GrantCommon Stock	55,000	$0.00	$0.00	Disclosure SEC source: 0001209191-23-005332 · doc4a.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,755 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 19, 2024, 6.25% of the shares every three months thereafter beginning on April 19, 2024 and ending on January 19, 2025, and 12.5% of the shares every three months thereafter beginning on April 19, 2025 and ending on January 19, 2026. F2 · balance_after: Represents 22,242 shares of common stock and 75,513 restricted stock units. Read SEC document
December 27, 2022 Filed Dec 27, 2022 16:05 UTC	ALBIREO PHARMA, INC. ALBO · Entity 116015	SaleCommon Stock	469	$19.06	$8,939.80	Disclosure SEC source: 0001209191-22-062701 · doc4.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,178 F1 · shares: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Represents 18,921 shares of common stock and 26,257 restricted stock units. Read SEC document
December 27, 2022 Filed Jan 9, 2023 18:42 UTC Amendment	ALBIREO PHARMA, INC. ALBO · Entity 116015	SaleCommon Stock	469	$19.06	$8,939.80	Disclosure SEC source: 0001209191-23-002636 · doc4a.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,631 F1 · shares: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Represents 18,374 shares of common stock and 26,257 restricted stock units. Read SEC document
October 24, 2022 Filed Oct 25, 2022 16:00 UTC	ALBIREO PHARMA, INC. ALBO · Entity 116015	SaleCommon Stock	104	$19.58	$2,035.95	Disclosure SEC source: 0001209191-22-054491 · doc4.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,647 F1 · shares: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Represents 17,828 shares of common stock and 27,819 restricted stock units. Read SEC document
September 26, 2022 Filed Sep 27, 2022 16:01 UTC	ALBIREO PHARMA, INC. ALBO · Entity 116015	SaleCommon Stock	445	$19.40	$8,635.18	Disclosure SEC source: 0001209191-22-051349 · doc4.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,751 F1 · shares: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.3691 to $19.405, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: Represents 17,588 shares of common stock and 28,163 restricted stock units. Read SEC document
July 22, 2022 Filed Jul 25, 2022 16:14 UTC	ALBIREO PHARMA, INC. ALBO · Entity 116015	SaleCommon Stock	106	$24.67	$2,615.16	Disclosure SEC source: 0001209191-22-043102 · doc4.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,196 F1 · shares: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.67 to $24.7431, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: Represents 16,470 shares of common stock and 29,726 restricted stock units. Includes 547 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan (the "ESPP") on May 31, 2022. Read SEC document
July 22, 2022 Filed Jan 9, 2023 18:41 UTC Amendment	ALBIREO PHARMA, INC. ALBO · Entity 116015	SaleCommon Stock	106	$24.67	$2,615.16	Disclosure SEC source: 0001209191-23-002635 · doc4a.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,649 F1 · shares: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.67 to $24.7431, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: Represents 15,923 shares of common stock and 29,726 restricted stock units. Read SEC document
June 27, 2022 Filed Jun 28, 2022 16:02 UTC	ALBIREO PHARMA, INC. ALBO · Entity 116015	SaleCommon Stock	461	$19.47	$8,975.67	Disclosure SEC source: 0001209191-22-039597 · doc4.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,755 F1 · kind: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Represents 15,685 shares of common stock and 30,070 restricted stock units. Read SEC document
June 14, 2022 Filed Jun 16, 2022 21:51 UTC	Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058	GrantStock Option (right to buy) · Derivative	34,663	$0.00 Strike: $1.01	$0.00	Disclosure SEC source: 0001062993-22-015040 · form4.xml · derivative · entry 3 Stephenson Pamela · CIK 0001767650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,663 Underlying: Common Stock · 34,663 shares Expires 2032-06-14 F3 · derivative.exercise_date: The option vests in full upon the earlier of (i) June 14, 2023 or (ii) the day before the Company's 2023 annual meeting of stockholders. Read SEC document
June 14, 2022 Filed Jun 16, 2022 21:51 UTC	Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058	SaleCommon Stock	40	$1.01	$40.40	Disclosure SEC source: 0001062993-22-015040 · form4.xml · nonDerivative · entry 2 Stephenson Pamela · CIK 0001767650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,069 F2 · shares: This transaction represents shares required to be sold by the Reporting Person to satisfy certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person. Read SEC document
June 14, 2022 Filed Jun 16, 2022 21:51 UTC	Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058	GrantCommon Stock	23,109	$0.00	$0.00	Disclosure SEC source: 0001062993-22-015040 · form4.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,109 F1 · shares: The restricted stock award vests in full upon the earlier of (i) June 14, 2023 or (ii) the day before the Company's 2023 annual meeting of stockholders. Read SEC document
April 22, 2022 Filed Apr 25, 2022 16:40 UTC	ALBIREO PHARMA, INC. ALBO · Entity 116015	SaleCommon Stock	103	$32.92	$3,391.24	Disclosure SEC source: 0001209191-22-025524 · doc4.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,216 F1 · shares: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Represents 14,584 shares of common stock and 31,632 restricted stock units. Read SEC document
March 28, 2022 Filed Mar 29, 2022 16:00 UTC	ALBIREO PHARMA, INC. ALBO · Entity 116015	SaleCommon Stock	454	$30.53	$13,858.35	Disclosure SEC source: 0001209191-22-021442 · doc4.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,319 F1 · shares: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: 14,344 shares of common stock and 31,975 restricted stock units. Read SEC document
January 24, 2022 Filed Jan 25, 2022 16:38 UTC	ALBIREO PHARMA, INC. ALBO · Entity 116015	SaleCommon Stock	416	$24.88	$10,351.00	Disclosure SEC source: 0001209191-22-004805 · doc4.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,773 F1 · shares: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.7811 to $24.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: 13,235 shares of common stock and 33,538 restricted stock units. Read SEC document
January 18, 2022 Filed Jan 20, 2022 16:49 UTC	ALBIREO PHARMA, INC. ALBO · Entity 116015	GrantCommon Stock	21,600	$0.00	$0.00	Disclosure SEC source: 0001209191-22-004055 · doc4.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,189 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 18, 2023, with the remainder vesting in equal installments every three months thereafter beginning on April 18, 2023 and ending on January 18, 2026. F2 · balance_after: 12,276 shares of common stock and 34,913 restricted stock units. Read SEC document
December 27, 2021 Filed Dec 27, 2021 16:02 UTC	ALBIREO PHARMA, INC. ALBO · Entity 116015	SaleCommon Stock	474	$23.92	$11,339.45	Disclosure SEC source: 0001209191-21-071236 · doc4.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,589 F1 · kind: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: 12,276 shares of common stock and 13,313 restricted stock units. Read SEC document
September 27, 2021 Filed Sep 28, 2021 16:32 UTC	ALBIREO PHARMA, INC. ALBO · Entity 116015	SaleCommon Stock	451	$32.05	$14,456.22	Disclosure SEC source: 0001209191-21-057934 · doc4.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,063 F1 · kind: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: 11,188 shares of common stock and 14,875 restricted stock units. Read SEC document
August 03, 2021 Filed Aug 5, 2021 17:29 UTC	Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058	GrantStock Option (right to buy) · Derivative	7,500	$0.00 Strike: $4.44	$0.00	Disclosure SEC source: 0001192482-21-000647 · edgar.xml · derivative · entry 2 Stephenson Pamela · CIK 0001767650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2031-08-03 F2 · derivative.exercise_date: The option vests in full upon the earlier of (i) August 3, 2022, or (ii) the day before the Company's 2022 annual meeting of stockholders. Read SEC document
August 03, 2021 Filed Aug 5, 2021 17:29 UTC	Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058	GrantCommon Stock	5,000	$0.00	$0.00	Disclosure SEC source: 0001192482-21-000647 · edgar.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: The restricted stock award vests in full upon the earlier of (i) August 3, 2022, or (ii) the day before the Company's 2022 annual meeting of stockholders. Read SEC document
June 25, 2021 Filed Jun 28, 2021 16:02 UTC	ALBIREO PHARMA, INC. ALBO · Entity 116015	SaleCommon Stock	471	$36.01	$16,960.71	Disclosure SEC source: 0001209191-21-043468 · doc4.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,514 F1 · kind: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: 10,076 shares of common stock and 16,438 restricted stock units. Read SEC document
March 29, 2021 Filed Mar 31, 2021 19:21 UTC	ALBIREO PHARMA, INC. ALBO · Entity 116015	SaleCommon Stock	422	$34.02	$14,355.34	Disclosure SEC source: 0001209191-21-023871 · doc4.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,985 F1 · shares: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Represents 8,985 shares of common stock and 18,000 restricted stock units. Read SEC document
January 21, 2021 Filed Jan 25, 2021 17:34 UTC	ALBIREO PHARMA, INC. ALBO · Entity 116015	GrantStock Option (right to buy) · Derivative	23,700	$0.00 Strike: $34.88	$0.00	Disclosure SEC source: 0001209191-21-005150 · doc4.xml · derivative · entry 2 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,700 Underlying: Common Stock · 23,700 shares Expires 2031-01-20 F2 · derivative.exercise_date: This option vests as to 25% of the shares on January 21, 2022, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2022 and ending on January 21, 2025. Read SEC document
January 21, 2021 Filed Jan 25, 2021 17:34 UTC	ALBIREO PHARMA, INC. ALBO · Entity 116015	GrantCommon Stock	5,500	$0.00	$0.00	Disclosure SEC source: 0001209191-21-005150 · doc4.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,407 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 21, 2022, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2022 and ending on January 21, 2025. Read SEC document
December 28, 2020 Filed Dec 29, 2020 16:19 UTC	ALBIREO PHARMA, INC. ALBO · Entity 116015	SaleCommon Stock	460	$39.07	$17,974.13	Disclosure SEC source: 0001209191-20-065364 · doc4.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,907 F1 · kind: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F1 · shares: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Represents 7,844 shares of common stock and 14,063 restricted stock units. Read SEC document
September 25, 2020 Filed Sep 25, 2020 17:05 UTC	ALBIREO PHARMA, INC. ALBO · Entity 116015	SaleCommon Stock	451	$33.20	$14,973.20	Disclosure SEC source: 0001209191-20-052109 · doc4.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,367 F1 · kind: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Represents 6,742 shares of common stock and 15,625 restricted stock units. Read SEC document
June 25, 2020 Filed Jun 26, 2020 17:02 UTC	ALBIREO PHARMA, INC. ALBO · Entity 116015	SaleCommon Stock	397	$30.79	$12,223.63	Disclosure SEC source: 0001209191-20-039107 · doc4.xml · nonDerivative · entry 1 Stephenson Pamela · CIK 0001767650 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,818 F1 · kind: Shares sold pursuant to a Rule 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.75 to $30.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: Represents 5,630 shares of common stock and 17,188 restricted stock units. Read SEC document
June 10, 2020 Filed Jun 11, 2020 17:36 UTC	Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $5.21	$0.00	Disclosure SEC source: 0001192482-20-000467 · edgar.xml · derivative · entry 1 Stephenson Pamela · CIK 0001767650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: The option vests upon the earlier of (i) June 10, 2021 and (ii) the day before the Company's 2021 annual meeting of stockholders. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.